ConsumerLab.com uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.

About ConsumerLab.com

Posted October 11, 2016

Seller of Glucosamine and Chondroitin Settles FTC Charges of False Advertising

On October 5, 2016, the FTC announced the sellers of the liquid glucosamine and chondroitin supplement Supple (Supple LLC) agreed to settle charges they made false claims about the product.

Supple cost $70 for a 24 day supply and was promoted on the internet, social media and through infomercials and in-person events. According to the FTC, the company did not have adequate evidence to support its claims the supplement could provide complete relief from chronic and severe joint pain caused by arthritis and fibromyalgia and was scientifically proven to eliminate joint pain. In the infomercial, one company principal of the company acted as medical-show style host and the other as a guest, and claimed, among other things, the supplement could "repair cartilage; rebuild joints and entire joint structures, and restores mobility and joint function to consumers with severe mobility restrictions."

The court order requires Supple LLC to have scientific evidence for any future claims made about the product, and includes a $150 million judgement — although this was suspended due to the financial status of the company.

See Related Warnings:

No Evidence Supplement Can Reverse or Prevent Gray Hair, Says FTC

Supplements to Eliminate Gray Hair Not Supported by Science, Says FTC

Marketers of Nopal Cactus Drink Settle FTC Charges of Deceptive Claims

FTC Mails Refund Checks for Calcium Supplements

FTC Files Against Maker of Calcium and Fertility Supplements

Restitution Program for Purchases of Lane Labs' Products

FTC Mails Refund Checks to Consumers Who Purchased Weight Loss Pills

FTC Mails Refund Checks to Consumers Who Purchased Sensa

Four Companies Settle FTC Charges of Deceptive Weight Loss Claims

Sensa Settles Second False Advertising Lawsuit

To read the FTC's press release, use the link below.